Macrogenics Aktie

Macrogenics für 0 Euro bei ZERO ordern (zzgl. Spreads)

WKN DE: A1W6ND / ISIN: US5560991094

<
Kurse + Charts + Realtime
Kurs + Chart
Times + Sales
Börsenplätze
Historisch
>
<
News + Analysen
News + Adhoc
Analysen
Kursziele
>
<
Unternehmen
Termine
Profil
>
<
zugeh. Wertpapiere
Zertifikate
Optionsscheine
Knock-Outs
>
14.08.2025 22:21:02

MacroGenics Revenue Doubles in Q2

MacroGenics (NASDAQ:MGNX), a biotechnology company focused on antibody-based cancer treatments, reported its second-quarter results on August 14, 2025. The release showed GAAP revenue of $22.2 million, which fell well below Wall Street's GAAP projection of $31.7 million. The loss per share (GAAP) was $(0.57), also missing the $(0.42) GAAP EPS expected by analysts. While GAAP revenue more than doubled from the prior-year quarter, the results disappointed due to the complete absence of product sales following the company’s exit from its previous marketed product. Management pointed to lower operating costs as a bright spot, but overall, the quarter reflected difficulties in offsetting lost product revenue and underlined the company’s ongoing strategic transition. Source: Analyst estimates for the quarter provided by FactSet. MacroGenics develops monoclonal antibodies and antibody-drug conjugates to treat various forms of cancer. The company builds its business model around advancing clinical candidates through to late-stage development, then partnering or out-licensing these assets to larger firms for commercialization, often in exchange for milestone payments and royalties.Continue readingWeiter zum vollständigen Artikel bei MotleyFool

Analysen zu Macrogenics Incmehr Analysen

Eintrag hinzufügen
Hinweis: Sie möchten dieses Wertpapier günstig handeln? Sparen Sie sich unnötige Gebühren! Bei finanzen.net Brokerage handeln Sie Ihre Wertpapiere für nur 5 Euro Orderprovision* pro Trade? Hier informieren!
Es ist ein Fehler aufgetreten!

Aktien in diesem Artikel

Macrogenics Inc 1,41 -4,21% Macrogenics Inc
Q2 Holdings Inc 60,50 -2,42% Q2 Holdings Inc